Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COBIMETINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL vs COBIMETINIB: Safety Overview

Metric COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL COBIMETINIB
Total FAERS Reports 8,432 4,071
Deaths Reported 131 527
Death Rate 1.6% 12.9%
Hospitalizations 647 1,895
Average Patient Age 46.2 yrs 59.3 yrs
% Female Patients 25.3% 47.4%
FDA Approval Date N/A Nov 10, 2015
Manufacturer N/A Genentech, Inc.
Route N/A ORAL
Marketing Status N/A Prescription